N/A N=27 The Estrogen Impact on Overactive Bladder Syndrome: Female Pelvic Floor Microbiomes and Antimicrobial Peptides
Overactive Bladder
Primary: Change in the Relative Abundance of Lactobacillus — 0.143 proportion of total microbes
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=25 Preventing Recurrent UTI With Vaginal Estrogen
Recurrent Urinary Tract Infection · Urinary Tract Infections · Cystitis Recurrent
Primary: Change in Vaginal Microbiota — 2.75 change in percent relative abundance
N/A N=139 Evaluating the Effect of the Probiotic on Recurrent Urinary Tract Infection in Adult Women
Recurrent Urinary Tract Infection in Adult Women
Primary: To Evaluate the Effect of Oral Supplementation With Lactobacillus Reuteri on the Frequency of Confirmed UTI in Adult Women With Recurrent UTI. — 1.2; 1.3 Number of…
N/A N=100 Laser Therapy for Treatment of Urogenital Symptoms in Women
Genitourinary System; Disorder, Female · Burning Vagina · Dyspareunia
Primary: Patient Global Impression of Improvement (PGI-I) Score at 4 Weeks After Initial Treatment — 2.66 score on a scale
N/A N=16 Surface Stimulation for Female Sexual Dysfunction
Female Sexual Dysfunction
Primary: 6 Weeks - Total FSFI Score — 26.0; 17.4 score on a scale — p=0.109
Phase 4 N=84 Mirabegron and Urinary Urgency Incontinence
Overactive Bladder
Primary: Response to Therapy — 15; 29 Participants
N/A N=705 Women's Improvement of Sexual Health (WISH) Demonstration Project
Sexually Transmitted Disease · Bacterial Vaginosis · Vaginal Candidiasis
Primary: Feasibility of Integrating Point-of-care Testing (Monitoring & Evaluation Indicators) — 396; 378; 399; 216 Participants
N/A N=300 Single Dose Monurol for Treatment of Acute Cystitis
Urinary Tract Infection
Primary: Number of Participants Who Were Cured — 120; 130 Participants — p=<0.001
Phase 4 N=35 Investigation of the Effect of the Female Urinary Microbiome on Incontinence
Overactive Bladder · Incontinence · Nocturia
Primary: Change in the Relative Abundance of Lactobacillus — 0.275 proportion of total microbes
N/A N=56 Medication Effects on Periurethral Sensation,Urethral Sphincter Activity and Pressure Flow Parameters
Urethral Sphincter Activity
Primary: Difference (Pre - Post) in Amplitude (Microvolts) of Urethral Sphincter Activity as Measured by Quantitative Concentric Needle EMG — -18; 10; 11; -15 microvolts — p=>0.05
Phase 4 N=20 Inflammation in Women With Urgency Urinary Incontinence Treated With Anticholinergics
Urinary Incontinence · Urgency Urinary
Primary: Inflammatory Markers in Urine Will be Measured Using Immunoenzyme Assays to Measure the Interaction of Anticholinergic Treatment and the Inflammatory Milieu. — 2.192…
Phase 4 N=35 Vaginal Estrogen for the Prevention of Recurrent Urinary Tract Infection in Postmenopausal Women
Recurrent Urinary Tract Infection
Primary: Occurrence of UTI During Randomization — 8; 10 Participants
N/A N=351 Point of Care Diagnosis of Vaginal Infections
Vaginitis · Bacterial Vaginosis · Yeast Vaginitis
Primary: Number of Participants Prescribed Appropriate Treatment — 61; 104; 58; 21 Participants — p=<.001
N/A N=400 Improving Care for Women With Urinary Incontinence (EMPOWER)
Urinary Incontinence
Primary: Change in Patients' UI Symptoms as Measured by International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI SF) — 8.4; 9.0; 9.9; 8.9…
Phase 4 N=242 Cytoscopic Antibiotic Irrigant to Reduce Postoperative Urinary Tract Infection
Urinary Tract Infections
Primary: Urinary Tract Infection — 11; 12 UTI
N/A N=1,585 Clinical Study of a Diagnostic Device for NG, TV and CT in Women
Chlamydial Infection · Gonococcal Infection · Trichomoniasis
Primary: The i) Percent Sensitivity and ii) Percent Specificity of Click Device for Detection of Chlamydia Trachomatis (CT) in Self-collected Vaginal Specimens as Compared to PIS…
N/A N=12 Fractional CO2 Vaginal LASER Therapy for Recurrent Urinary Tract Infection
Urinary Tract Infections
Primary: Prevalence of Urinary Tract Infections (UTI) — 28.6; 60; 71.4; 40 percentage of subjects — p=0.034
Phase 4 N=163 Suppressive Therapy With Oral Antibiotics for Prevention of Postoperative Urinary Tract Infection (UTI)
Urinary Tract Infection
Primary: Urinary Tract Infections — 18; 10 participants
Phase 2 N=160 Preventing Urinary Tract Infection Post-Surgery
Urinary Tract Infection
Primary: Participants With Clinically-diagnosed and Treated UTI's. — 15; 30 participants
N/A N=100 Trial Comparing Outpatient Flexible to Rigid Cystoscopy in Females
Pain
Primary: Post Procedural Complications, Including Frequency, Urgency, Infection and Time to Resolution of These Symptoms Between the Two Procedures. — 17; 15; 5; 15 participants
Phase 4 N=138 Incontinence & Intimate Partners: Assessing the Contribution of Treatment
Urge Urinary Incontinence
Primary: Baseline Sexual Satisfaction Between Matched Female and Male Partners — 4.2; 4.8 score on a scale — p=.16
Phase 2 N=234 Topical Metronidazole and Miconazole Co-formulated Vaginal Suppositories for Preventing Vaginal Infections in HIV-seronegative Women
Bacterial Vaginosis · Candidiasis · Trichomoniasis
Primary: Efficacy of Monthly Periodic Presumptive Treatment (PPT) Using Metronidazole With Miconazole Intravaginal Suppositories Versus Matching Placebo Nightly for Five Nights…
Phase 3 N=97 A Study in Adolescent and Adult Female Participants to Evaluate Clinical Symptom Improvement and the Safety of Gepotidacin During Treatment of Uncomplicated Urinary Tract Infections (Acute Cystitis)
Urinary Tract Infections
Primary: Percentage of Participants Achieving Clinical Symptom Improvement at 24 Hours (±4 Hours) — 54.4 Percentage of participants
N/A N=250 Web-based Management of Female Stress Urinary Incontinence
Female Stress Urinary Incontinence
Primary: International Consultation on Incontinence Modular Questionnaire Urinary Incontinence Short Form (ICIQ-UI SF) — 10.3; 10.4; 7.3; 6.9 units on a scale — p=0.27
Phase 3 N=1,892 Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection
Sexually Transmitted Diseases · Gonorrhea · Chlamydia
Primary: Percentage of Study Successes in the EVO100 and Placebo Treatment Groups — 684; 696 Participants
Phase 4 N=645 Bringing Simple Urge Incontinence Diagnosis & Treatment to Providers (BRIDGES)
Urge Urinary Incontinence · Overactive Bladder
Primary: Change in Frequency of Urge Urinary Incontinence Episodes at Week 12. — -2.5; -1.8 episodes — p=<0.001
Phase 2 N=134 Bacterial Genomic Sequencing in Overactive Bladder
Overactive Bladder
Primary: Bacterial Genomic Sequencing — 25; 11; 3; 6 participants
Phase 3 N=302 The Vaginal Health Trial
Atrophy of Vagina · Menopause · Dyspareunia (Female)
Primary: Most Bothersome Symptom (MBS) Severity — -1.2; -1.0; -0.2; -1.4 units on a scale — p=0.25
Phase 2 N=100 Intravaginal LACTIN-V for Prevention of Recurrent Urinary Tract Infection
Urinary Tract Infection
Primary: Incidence of Urinary Tract Infection — 7; 13 participants
N/A N=66 Impact of Decision Aids in Urogynecology
Pelvic Organ Prolapse · Stress Urinary Incontinence · Overactive Bladder
Primary: Patient Knowledge — 60; 72 percentage of questions answered correct — p=0.06